Cargando…
Pharmacomicrobiomics: a novel route towards personalized medicine?
Inter-individual heterogeneity in drug response is a serious problem that affects the patient’s wellbeing and poses enormous clinical and financial burdens on a societal level. Pharmacogenomics has been at the forefront of research into the impact of individual genetic background on drug response va...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Higher Education Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960471/ https://www.ncbi.nlm.nih.gov/pubmed/29705929 http://dx.doi.org/10.1007/s13238-018-0547-2 |
_version_ | 1783324585306882048 |
---|---|
author | Doestzada, Marwah Vila, Arnau Vich Zhernakova, Alexandra Koonen, Debby P. Y. Weersma, Rinse K. Touw, Daan J. Kuipers, Folkert Wijmenga, Cisca Fu, Jingyuan |
author_facet | Doestzada, Marwah Vila, Arnau Vich Zhernakova, Alexandra Koonen, Debby P. Y. Weersma, Rinse K. Touw, Daan J. Kuipers, Folkert Wijmenga, Cisca Fu, Jingyuan |
author_sort | Doestzada, Marwah |
collection | PubMed |
description | Inter-individual heterogeneity in drug response is a serious problem that affects the patient’s wellbeing and poses enormous clinical and financial burdens on a societal level. Pharmacogenomics has been at the forefront of research into the impact of individual genetic background on drug response variability or drug toxicity, and recently the gut microbiome, which has also been called the second genome, has been recognized as an important player in this respect. Moreover, the microbiome is a very attractive target for improving drug efficacy and safety due to the opportunities to manipulate its composition. Pharmacomicrobiomics is an emerging field that investigates the interplay of microbiome variation and drugs response and disposition (absorption, distribution, metabolism and excretion). In this review, we provide a historical overview and examine current state-of-the-art knowledge on the complex interactions between gut microbiome, host and drugs. We argue that combining pharmacogenomics and pharmacomicrobiomics will provide an important foundation for making major advances in personalized medicine. |
format | Online Article Text |
id | pubmed-5960471 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Higher Education Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-59604712018-05-25 Pharmacomicrobiomics: a novel route towards personalized medicine? Doestzada, Marwah Vila, Arnau Vich Zhernakova, Alexandra Koonen, Debby P. Y. Weersma, Rinse K. Touw, Daan J. Kuipers, Folkert Wijmenga, Cisca Fu, Jingyuan Protein Cell Review Inter-individual heterogeneity in drug response is a serious problem that affects the patient’s wellbeing and poses enormous clinical and financial burdens on a societal level. Pharmacogenomics has been at the forefront of research into the impact of individual genetic background on drug response variability or drug toxicity, and recently the gut microbiome, which has also been called the second genome, has been recognized as an important player in this respect. Moreover, the microbiome is a very attractive target for improving drug efficacy and safety due to the opportunities to manipulate its composition. Pharmacomicrobiomics is an emerging field that investigates the interplay of microbiome variation and drugs response and disposition (absorption, distribution, metabolism and excretion). In this review, we provide a historical overview and examine current state-of-the-art knowledge on the complex interactions between gut microbiome, host and drugs. We argue that combining pharmacogenomics and pharmacomicrobiomics will provide an important foundation for making major advances in personalized medicine. Higher Education Press 2018-04-28 2018-05 /pmc/articles/PMC5960471/ /pubmed/29705929 http://dx.doi.org/10.1007/s13238-018-0547-2 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Review Doestzada, Marwah Vila, Arnau Vich Zhernakova, Alexandra Koonen, Debby P. Y. Weersma, Rinse K. Touw, Daan J. Kuipers, Folkert Wijmenga, Cisca Fu, Jingyuan Pharmacomicrobiomics: a novel route towards personalized medicine? |
title | Pharmacomicrobiomics: a novel route towards personalized medicine? |
title_full | Pharmacomicrobiomics: a novel route towards personalized medicine? |
title_fullStr | Pharmacomicrobiomics: a novel route towards personalized medicine? |
title_full_unstemmed | Pharmacomicrobiomics: a novel route towards personalized medicine? |
title_short | Pharmacomicrobiomics: a novel route towards personalized medicine? |
title_sort | pharmacomicrobiomics: a novel route towards personalized medicine? |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5960471/ https://www.ncbi.nlm.nih.gov/pubmed/29705929 http://dx.doi.org/10.1007/s13238-018-0547-2 |
work_keys_str_mv | AT doestzadamarwah pharmacomicrobiomicsanovelroutetowardspersonalizedmedicine AT vilaarnauvich pharmacomicrobiomicsanovelroutetowardspersonalizedmedicine AT zhernakovaalexandra pharmacomicrobiomicsanovelroutetowardspersonalizedmedicine AT koonendebbypy pharmacomicrobiomicsanovelroutetowardspersonalizedmedicine AT weersmarinsek pharmacomicrobiomicsanovelroutetowardspersonalizedmedicine AT touwdaanj pharmacomicrobiomicsanovelroutetowardspersonalizedmedicine AT kuipersfolkert pharmacomicrobiomicsanovelroutetowardspersonalizedmedicine AT wijmengacisca pharmacomicrobiomicsanovelroutetowardspersonalizedmedicine AT fujingyuan pharmacomicrobiomicsanovelroutetowardspersonalizedmedicine |